The expert opinion algorithm the authors propose includes IL-17 inhibitors as a first option and IL-23 inhibitors as a second therapeutic option for patients with psoriasis and concomitant hepatitis B virus infection, while TNF-alpha inhibitors should be avoided [68]. Here, IL17A is linked to psoriasis.